Microglial activation, increased proinflammatory cytokine production, and a reduction in synaptic density are key pathological features associated with HIV-associated neurocognitive disorders (HAND). Even with combination antiretroviral therapy (cART), more than 50% of HIVpositive individuals experience some type of cognitive impairment. Although viral replication is inhibited by cART, HIV proteins such as Tat are still produced within the nervous system that are neurotoxic, involved in synapse elimination, and provoke enduring neuroinflammation. As complement deposition on synapses followed by microglial engulfment has been shown during normal development and disease to be a mechanism for pruning synapses, we have tested whether complement is required for the loss of synapses that occurs after a cortical Tat injection mouse model of HAND. In Tat-injected animals evaluated 7 or 28 days after injection, levels of early complement pathway components, C1q and C3, are significantly elevated and associated with microgliosis and a loss of synapses. However, C1qa knockout mice have the same level of Tat-induced synapse loss as wild-type (WT) mice, showing that the C1q-initiated classical complement cascade is not driving synapse removal during HIV1 Tat-induced neuroinflammation.
| INTRODUCTION
Although the field of neuroAIDS has been transformed by antiretroviral therapies, cognitive impairments associated with HIV infection remain a major concern. About 50% of HIV+ patients on cART have neurological symptoms such as impaired learning and memory and psychomotor slowing (Spudich, 2013) . The degree of cognitive impairments in HAND correlates with increased populations of activated microglia/macrophages and with synaptic and dendritic injury rather than neuronal loss (An et al., 1996; Everall et al., 1999; Sa et al., 2004) . Thus, adjunctive treatments are needed to protect the central nervous system (CNS) from inflammatory damage with associated cognitive decline and the complement pathway offers an attractive set of targets for therapeutic intervention.
HIV enters the CNS via infected monocytes and lymphocytes that traverse the blood-brain barrier (Jones & Power, 2006) . Although cART suppresses viral replication, some viral proteins such as Tat, are still made by infected macrophages, microglia, and astrocytes. Viral proteins released from infected glia can harm adjacent neurons directly or indirectly by activating the immune system and triggering the production of cytokines, complement proteins, and reactive oxygen species (Bansal et al., 2000; Buscemi, Ramonet, & Geiger, 2007; Chen, Partridge, Sell, Torres, & Martin-Garcia, 2017; Jadhav, Krause, & Singh, 2014; Marker et al., 2013; Nitkiewicz et al., 2017; Williams et al., 2010; Youn, Ju, Choi, & Park, 2015) . Simply exposing the brain to Tat causes neuropathologic changes that are relevant to HAND.
Specifically, transgenic mice that express Tat in astrocytes have impaired learning and memory, dendritic spine reductions, changes in synaptic protein expression, microglia and astrocyte activation, increased oxidative stress, reduced excitability or numbers of specific neuron subpopulations, and reductions in grey matter volumes (Bruce-Keller et al., 2008; Carey et al., 2013; Chivero et al., 2017; Dickens et al., 2017; Fatima et al., 2017; Fitting et al., 2013; Leibrand et al., 2017; Marks et al., 2016; Paris, Zou, Hahn, Knapp, & Hauser, 2016; Schier et al., 2017) .
Synapse loss and an enduring neuroinflammatory response also occur following a single injection of Tat (Aksenov et al., 2003; Lu et al., 2011; Pu et al., 2003) . The synapse loss begins as early as 24 hr after Tat exposure and is still prominent after 4 weeks. Microglia in Tat-injected brains have more phagocytic inclusions than in controls and some inclusions clearly contain synaptic vesicles Marker et al., 2013; Raybuck, Hargus, & Thayer, 2017; Tremblay et al., 2013) . This led us to investigate whether complement opsonization drives this microglia-mediated synapse phagocytosis as complement has been implicated in synaptic pruning or synaptic debris clearance in development, Alzheimer's, schizophrenia, frontotemporal dementia, aging, West Nile virus neuroinvasive disease, and following optic nerve injury (Hong et al., 2016; Lui et al., 2016; Norris et al., 2018; Sekar et al., 2016; Shi et al., 2015; Vasek et al., 2016) . Microglialmediated synaptic pruning requires the early complement cascade components C1q, C3, C4, and the microglia-specific complement receptor 3 (Schafer & Stevens, 2010; Stevens et al., 2007) .
Previous work has provided correlative support for complement species being dysregulated in the CNS after HIV-1 infection. Elevated levels of C1q were found in the cerebrospinal fluid (CSF) of young, cognitively impaired, HIV+ patients when compared to seropositive patients that were cognitively normal (McGuire, Gill, Douglas, Kolson, & Group, 2016) . In contrast, the reports on C3 levels in the CSF of HIV+ patients have been mixed with some studies showing increased levels (Jongen et al., 2000) and others decreased levels (Reboul et al., 1989; Rozek et al., 2007) that likely reflect the complex interplay between increased expression and enhanced activation/degradation of C3. Within brain parenchyma, multiple complement transcripts are upregulated in patients with HIV-1 encephalitis (Gelman et al., 2012; Mahajan et al., 2017) , a neuropathologic entity that occurs infrequently since the advent of cART. Whether aberrant complement deposition represents a penultimate step in synapse removal associated with HIV infection remains an essential unanswered question because synaptic architecture and function are the key pathologic substrates for HAND.
In this study, we demonstrate that the neuroinflammatory response after Tat injection into the cortex of mice is associated with increased C1q and C3 expression. However, genetic deletion of C1q does not prevent Tat-induced synapse loss. In turn, our data provide a counterpoint to the idea that complement deposition is a "final common pathway" event to synapse loss in the context of neuroinflammation. 
| METHODS

| Animals
| Experimental design and statistical analysis
Mice were 8-14 weeks at the start of all experiments. Male mice were used for chimera immunohistochemistry (IHC) experiments in Figure 1 . A mix of male and female mice was used for the remaining C1qa knockout versus WT experiments. N values (number of animals) for each experiment are reported in the figure legends. GraphPad Prism software was used to perform all statistics. We defined significance as p < .05. Student's t test was used when comparing only two groups. One-way ANOVA followed by Tukey's multiple comparisons test was done for western blot data. Two-way ANOVAs were done when comparing IHC data from WT and C1qa KO mice injected with Tat or saline. The two-way ANOVAs were followed by Holms-Sidak's multiple comparisons test with 4 comparisons done per family (WTsaline vs WT-Tat; C1qa KO-saline vs C1qa KO-Tat; WT-saline vs C1qa KO-saline; WT-Tat vs C1qa KO Tat). All data are expressed as the mean AE standard error of the mean (SEM).
| HIV-1 Tat 1-101 purification
His-tagged Tat 1-101 protein was made by first subcloning Tat cDNA into the p#T28a vector using Nhe1 and XhoI restriction sites and the PCR primers: 5 0 -CCCTAGCTAGCATGGA ACCGGTGGA TCCGAACC-3 0 and 5 0 -GGCCGCTCGAGTTATTAATGCACCGGATCGGTTTC GG-3 0 .
His-tagged Tat 1-101 protein was purified from BL21-Gold (DE3) bacteria transformed with the p#T28a-Tat plasmid by lysing cells with a
French press into a solution of 5 mM imidazole, 200 μM PMSF, 200 μM DTT, in dPBS, pH = 8 and running supernatant-containing Histagged Tat 1-101 on a Bio-Rad Profinia with IMAC column (BioRad, 610) and eluting with 300 mM imidazole in dPBS, pH = 8. Endotoxin was removed by adding CaCl 2 and sodium citrate to a final concentration of 1 mM and passing sample through an EndoTrap HD column (Hyglos, # 800053). Excess salt and imidazole were removed by passing samples through PD-10 columns (GE Healthcare, #17-0851-0), and eluting with 100 mM ammonium bicarbonate in endotoxin-free H 2 O (Hyclone, SH30529.02). Purified protein was aliquoted using siliconized tips, lyophilized overnight, and stored at −80 C.
| Bone marrow chimeras
CD45.1 mice were engrafted with heterozygous CX 3 CR1/GFP +/− bone marrow as described previously Marker et al., 2013 
| Stereotactic injection of Tat or saline
Three microliters of HIV-1 Tat or saline (0.9% NaCl) was stereotactically injected into the cortex at the coordinates 1.0 mm posterior to bregma, 1.0 mm lateral left of bregma, and 0.7 mm ventral to the pial surface as described previously Marker, Tremblay, Lu, Majewska, & Gelbard, 2010; Marker et al., 2013 When using 4×-20× objectives, one image per mouse was taken at each location relative to the injection site using identical light intensity and exposure settings for all animals within each image set. For 60×
images, 3 image stacks (10 μm thick; z-step = 0.3 μm) were collected at each location (at the injection site, 150 μm lateral, and 300 μm lateral). All image stacks are displayed as maximum intensity protections.
IBA1+ cell morphology measurements (surface area and volume) were obtained using an intensity-based automated segmentation algorithm in Volocity ("find objects") followed by a fine filter. Piccolo puncta were identified using the "find spots" algorithm in Volocity software, which identifies puncta based on local intensity maxima that also exceed an intensity threshold value. These two functions were combined to identify the Piccolo puncta that co-localize with IBA1+ cells. These aggregates could represent synaptic debris or simply the remaining synapses that acquire more Piccolo as neighboring synapses from the same axon are lost. WT and C1qa KO mice had similarly increased volumes of these Piccolo aggregates after Tat exposure at the injection site (ANOVA results indicate no variation attributed to genotype or interactions between genotype and injection treatment).
| C1qa KO does not prevent loss of multiple synaptic markers 7 days after Tat injection
Next we used western blots of cortical lysates from control and Tatinjected WT and C1qa KO mice to determine if there were changes in synaptic protein levels or markers of immune cell activation (Figure 3 ).
We collected 3 mm cortical biopsies surrounding the injection site, 7 days after Tat injection from WT or C1qa KO mice. We observed that Tat Statistical analysis for all graphs: Two-way ANOVAs were performed at each location with n = 6-7 animals per group using genotype and injection type as the independent variables. Significant main effects were found for the Tat versus saline injection (p < .05-grey #). There were no significant main effects due to genotype and no significant interactions between the injection type and genotype. The ANOVAs were followed by Holmes-Sidak multiple comparisons tests. *p < .05, **p < .01. (g) IHC with antibodies to C1q on brain sections from Tat-or salineinjected mice show that no C1q is expressed in C1qa KO mice compared to WT mice. Images show cortex and hippocampus. 4× magnification; scale bars = 60 μm For markers of microglial activation, we measured relative expression of IBA1 and IL-1β as well as at putative markers/stimulators of phagocytic, alternatively activated microglia, namely, Arg1 and IL-10, respectively (Figure 3e,f ) . In general, protein levels were elevated for IBA1 (two-to threefold), IL-1β (ninefold), Arg1 (40-to 60-fold), and IL-10 (1.5-fold) in both WT and C1qa KO Tat-injected animals compared to saline-injected controls, although there was substantial animal-toanimal variability. Genetic deletion of C1qa did not protect against
Tat-induced increases in IL-1β or Arg1, but C1q KO mice had less IBA1 expression than WT (WT-Tat = 3.33-fold vs C1qaKO-Tat = 2.27-fold increase over control; p = .0576 [Tukey's]).
| Piccolo puncta and aggregates overlapping IBA1+ cells
Previous studies have suggested that C1q helps microglia engulf synaptic elements. Thus, we investigated whether there was a difference in the number of Piccolo puncta co-localized with microglia in WT and C1qa KO mice injected with saline or Tat (Figure 4) . We found the percent of Piccolo puncta co-localizing with IBA1+ cells increased from 1.68% AE 0.4% in WT saline-injected controls to 13.3% AE 2.6%
in WT Tat-injected animals ( Figure 4c ). C1qa KO mice showed the same trend with 2.4% AE 0.7% in saline-injected controls and 12.3% AE 5.5% in Tat-injected animals. Two-way ANOVA shows there is no significant main effects of genotype on the co-localization of Pic- 3.5 | Both C1qa KO and WT animals have elevated C3 expression in response to TAT exposure, but C1qa KOs have significantly less C3 activation
The complement cascade can be initiated through three separate pathways (the classical pathway that requires C1q, the alternative pathway, and the lectin pathway) that all converge with activation of a C3 convertase that cleaves C3 to create the chemokine, C3a, and the opsonin that aids phagocytosis, C3b. C3b is inactivated by further cleavage that creates the fragments iC3b, C3c, and C3d (see diagram in Figure 5c ). We next investigated whether C1qa KO altered C3 expression or activation in response to Tat ( Figure 5 ). Using IHC at 28 days after injection, Tat-treated WT mice had significantly more C3 at the injection site than saline-injected animals (C3 fluorescence intensity: WT-Tat: 1,519 AE 400; WT-saline: 402 AE 77; p < .0178).
Tat-injected C1qa KO mice also had more C3 than saline-injected C1qa KO controls (C1qa KO-Tat 917 AE 275; C1qa KO-saline 399 AE 43.6; p = .248); but they also had less C3 than Tat-injected WT mice; (C1qa KO-Tat vs WT-Tat p = .248). These latter comparisons suggest that loss of C1q partially protects against C3 deposition;
however, the data only show trends as they do not reach statistical significance. With IHC, we cannot tell whether the detected C3 is full length C3 or whether it is a cleaved form of C3 downstream of activation. Therefore, we further analyzed C3 levels by western blot using samples collected at 7 days post injection. Tat injection results in elevated levels of full length C3 (α chain) in both WT and C1qa KO mice compared to WT saline-injected controls (Figure 5d ,e) (WTTat = 1.9-fold above control; p = .001; C1qa KO-Tat = 2.4-fold above control; p < .001). Using an antibody to the C3d region (which also detects full length C3 and the α 0 1 fragment of iC3b), we found that WT mice injected with Tat rather than saline have a significant increase in C3 cleavage products representing chronic complement pathway activation (α 0 1 = 13.2-fold increase, p = .018; C3d = 11.1-fold increase, p = .01 [Tukey's] ). While C1qKO mice injected with Tat also had some elevated levels of the α 0 1 and C3d cleavage products, the increase was no longer significant from salineinjected controls (α 0 1 = 5.83-fold increase, p = .40; C3d = 5.8-fold increase, p = .224) and trended less than Tat-injected WT mice (α 0 1 p = .14; C3d, p = .17). The decreased C3 activation products in the Tat-injected C1qaKO mice compared to WT mice indicates that the C1q-dependent classical pathway is partially responsible for activating C3 downstream of Tat. As there is still some C3 cleavage occurring in C1qa KO mice, the alternative and/or lectin pathways remain active.
Taken together, we conclude that Tat injection results in increased C3
expression, but knockout of C1qa partially prevents C3 activation.
This lower level of activation at 1 week post injection in C1qa KO animals could contribute to the decreased C3 fluorescence we observed at 28 days by IHC.
| DISCUSSION
Our previous research studies designed to investigate mechanisms responsible for HAND pathology using the simplified Tat-injection mouse model allowed us to determine that microglia/infiltrating monocyte-derived macrophages were responsible for clearing synapses or synaptic debris via phagocytosis Tremblay et al., 2013) . As complement has been widely implicated in synaptic pruning in development and multiple neuroinflammatory diseases, we investigated whether complement activation was also involved in HIV1 Tat-induced synapse loss.
We report here the complement proteins C1q and C3 were both highly elevated at the Tat injection site where synapse loss and infiltrating peripheral monocytes were maximal. Elevated C1q protein levels were also found at locations more distant from the injection site where synapse numbers were unaffected. Complement proteins are known to be up-regulated by many inflammatory signals. Expression of the C1q genes is controlled by the transcription factor MafB, as well as, by IRF8, PU.1,and multiple nuclear receptors, such as PPARδ, RXRα, RAR, and LXRα (G. Chen, Tan, Teh, & Lu, 2011; Mukundan et al., 2009; Tran et al., 2017) . C3 has been shown to be induced in astrocytes in vitro by HIV Tat downstream of NF-κB and IL-6 (Nitkiewicz et al., 2017) . We found at the Tat injection site, C1q and C3 were both diffusely located throughout the neuropil.
By comparing synapse loss in response to Tat exposure in WT and C1qa KO animals we found that Tat-induced synapse loss occurred independent of C1q and was largely restricted to the central injection site and adjacent regions up to 150 μm away. Specifically, we found that the levels of multiple synaptic proteins were decreased after Tat exposure in both WT and C1qa KO mice, and in particular, the number of Piccolo-positive synaptic puncta was significantly decreased after Tat injection independent of genotype (WT vs C1qa KO). The percentage of Piccolo puncta or aggregates co-localizing with microglia or monocyte-derived macrophages, representing both engulfed and contacted synapses, were increased by Tat exposure, but again independent of genotype (WT vs C1qa KO). Thus, synapse loss can occur during Tat-induced inflammation in the absence of C1q, and elevated C1q expression is not directly linked to synapse elimination. These results caution against concluding that when elevated C1q and decreased synaptic density are correlated in human pathology that the relationship is always causative.
Tat injection results in persistent neuroinflammation that involves not only activation of microglia but also infiltration of peripheral immune cells Marker et al., 2013 (Hong et al., 2016; Lui et al., 2016; Norris et al., 2018; Shi et al., 2015; Vasek et al., 2016) , it is curious that C1q is not required for even a portion of the significant synapse elimination that occurs in the Tat injection model of HAND. Yet genetic loss of C1q has also failed to protect against disease progression and reduced synaptic density in the mutant SOD1 mouse model of ALS (Lobsiger et al., 2013) . At this point, we cannot completely rule out a role for C3, the central hub of the complement cascade, or other complement proteins in Tat-induced synapse loss. Indeed, we did see that C3 levels were elevated by Tat at the injection site. However, as C1qa KO did partially limit C3 activation (measured as a decrease in C3d and α 0 1), but did not protect synapses, it seems unlikely that C3 is a primary Statistical analysis for all graphs: two-way ANOVAs were performed at each location with n = 6-7 animals per group using genotype and injection type as the independent variables. Significant main effects were found for the Tat versus saline injection (p < .05 grey #). There were no significant main effects due to genotype and no significant interactions between the injection type and genotype. The ANOVAs were followed by Holmes-Sidak multiple comparisons tests. *p < .05, **p < .01 driver for Tat-induced synapse loss via the lectin or alternative complement pathways. Other factors that may explain why C1q plays no role in this neuroinflammatory model, as opposed to other diseases with a neuroinflammatory component, include the significant infiltration of peripheral immune cells, differences in synaptic vulnerability in affected brain regions, possible redundant eat-me signals, and the direct neurotoxicity of Tat, which has been linked to NMDAR activation, Ca 2+ influx, mitochondrial dysfunction, and activation of the ubiquitin-proteasome pathway (reviewed in Ru & Tang, 2017) .
Going forward, it is important that we better understand the mechanisms by which HIV1 viral proteins such as Tat, that are present in the CNS of HIV+ patients even with virally suppressive cART, contribute to inflammation, dysregulated neural circuits, and synapse loss, so that we can successfully design adjunctive therapies to protect the brain. Ruling out mechanisms such as C1q-dependent, complementmediated elimination of synapses is an important part of this process that goes hand in hand with identifying the true molecular drivers of disease. 
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